Table 4.
Comparison of the LT recipients with negative and positive SARS-CoV-2 serology after vaccination. Patient characteristics are presented as absolute number n and percentage or median and interquartile range.
| Patient Characteristics | LT Recipients SARS-CoV-2 IgG Positive n/(%) |
LT Recipients SARS-CoV-2 IgG Negative n/(%) |
p-Value |
|---|---|---|---|
| Total patient number | 34 (79) | 9 (21) | - |
| Sex (male/female) | 20 (59)/14 (41) | 6 (67)/3 (33) | 1.00 |
| Immunosuppression | |||
| Tacrolimus (n = 40) | 31 (77.5) | 9 (22.5) | 1.00 |
| No Tacrolimus (n = 3) | 3 (100) | - | |
| Everolimus (n = 23) | 20 (87) | 3 (13) | 0.26 |
| No Everolimus (n = 20) | 14 (70) | 6 (30) | |
| MMF (n = 11) | 5 (45.5) | 6 (54.5) | 0.004 |
| No MMF (n = 32) | 29 (90.6) | 3 (9.4) | |
| Median (IQR) | Median (IQR) | ||
| Age of recipient at LT [years] | 48.5 (36–54) | 45 (40–55) | 0.97 |
| Time between LT and first dose [years] | 6.5 (3.7-12) | 12 (5.5-14.5) | 0.10 |
| Age at first dose [years] | 56.5 (46–64) | 59 (53.5-64.5) | 0.35 |
| Time between first and second doses [days] | 28 (21–37) | 21 (21–40) | 0.55 |
| Time between second dose and SARS-CoV-2 Ab detection [days] | 14 (12–25) | 15 (13–25) | 0.85 |
| SARS-CoV-2 IgG (BAU/mL) | 552.7 (137.3-1425) | - | - |
LT: liver transplantation; HCW: healthcare workers; Ab: antibody; BAU: binding antibody units; IQR: interquartile range.